Want to see NDRA full AI Analyst Report?
NDRA Stock Chart & Stats
$4.69
-$0.12(-1.95%)
At close: 4:00 PM EST
$4.69
-$0.12(-1.95%)
Day’s Range― - ―
52-Week Range$2.96 - $9.85
Previous CloseN/A
Volume13.45K
Average Volume (3M)514.97K
Market Cap
$6.05M
Enterprise Value$3.88M
Total Cash (Recent Filing)$356.46K
Total Debt (Recent Filing)$461.21K
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Aug 17, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.16
Shares Outstanding1,270,077
10 Day Avg. Volume1,472,495
30 Day Avg. Volume514,968
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.58
Price to Sales (P/S)0.00
P/FCF Ratio-0.69
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-97.58
Enterprise Value/Ebitda-0.54
Forecast
1Y Price Target
$25.00Price Target Upside433.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.65
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary TAEUS Imaging PlatformENDRA’s Thermo-Acoustic Enhanced Ultrasound (TAEUS) Nexus is a differentiated, non-invasive imaging platform targeting liver steatosis and fibrosis. A proprietary, clinically oriented device can support durable adoption in hospitals and research centers, enabling device placements, service contracts, and long-term product-led revenue streams if clinical utility gains traction.
Low Financial LeverageReported modest leverage (debt-to-equity around 0.26) limits near-term refinancing and interest burdens, giving ENDRA greater financial flexibility relative to highly levered peers. This reduces immediate solvency pressure and preserves optionality for strategic initiatives, M&A, or further commercialization spending without aggressive debt servicing constraints.
Committed Private Placement FinancingThe structured private placement (≈$3.8M) includes deposit control and an investor board observer, which materially improves near-term liquidity and governance oversight. This financing directly supports working capital, helps address Nasdaq equity thresholds, and provides a clearer runway to execute product development or pursue strategic transactions.
Bears Say
No Recurring RevenueAcross annual periods and TTM the company reports zero revenue and large net losses (~$7.3M TTM). The absence of a repeatable revenue base undermines sustainable cash generation, raises questions on product-market fit, and forces reliance on external financing to support operations and any commercialization push.
High Cash BurnSignificant negative operating (~-$5M TTM) and free cash flow (~-$8M TTM) indicate sizable ongoing funding needs. Persistent cash burn constrains the company’s ability to invest in sales, clinical validation, or scale manufacturing without dilutive financings, increasing execution risk and the likelihood of shareholder dilution over the medium term.
Strategic Pivot And Governance ConcentrationThe announced merger rebrands ENDRA into Noble Africa, shifting focus toward helium/gas development and creating an ownership/governance structure dominated by ASP Isotopes (~89% ownership, dual-class voting). This represents a structural change away from the diagnostics business, dilutes legacy shareholders' influence and adds execution and regulatory approval risk that could alter company strategy long-term.
ENDRA Life Sciences News
NDRA FAQ
What was ENDRA Life Sciences Inc’s price range in the past 12 months?
ENDRA Life Sciences Inc lowest stock price was $2.96 and its highest was $9.85 in the past 12 months.
What is ENDRA Life Sciences Inc’s market cap?
ENDRA Life Sciences Inc’s market cap is $6.05M.
When is ENDRA Life Sciences Inc’s upcoming earnings report date?
ENDRA Life Sciences Inc’s upcoming earnings report date is Aug 17, 2026 which is in 38 days.
How were ENDRA Life Sciences Inc’s earnings last quarter?
ENDRA Life Sciences Inc released its earnings results on May 18, 2026. The company reported -$1.09 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.09.
Is ENDRA Life Sciences Inc overvalued?
According to Wall Street analysts ENDRA Life Sciences Inc’s price is currently Undervalued.
Does ENDRA Life Sciences Inc pay dividends?
ENDRA Life Sciences Inc does not currently pay dividends.
What is ENDRA Life Sciences Inc’s EPS estimate?
ENDRA Life Sciences Inc’s EPS estimate is -0.84.
How many shares outstanding does ENDRA Life Sciences Inc have?
ENDRA Life Sciences Inc has 1,270,077 shares outstanding.
What happened to ENDRA Life Sciences Inc’s price movement after its last earnings report?
ENDRA Life Sciences Inc reported an EPS of -$1.09 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.129%.
Which hedge fund is a major shareholder of ENDRA Life Sciences Inc?
Currently, no hedge funds are holding shares in NDRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ENDRA Life Sciences Inc
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
NDRA Stock 12 Month Forecast
Average Price Target
$25.00
▲(433.05% Upside)
Technical Analysis
Ownership Overview
31.76% Insiders
0.83% Mutual Funds
4.09% Other Institutional Investors
62.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---